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Abstract. The microsatellite instability (MSI) phenotype 
may constitute an important biomarker for patient response 
to immunotherapy, particularly to anti-programmed death-1 
inhibitors. MSI is a type of genomic instability caused by a 
defect in DNA mismatch repair (MMR) proteins, which is 
present mainly in colorectal cancer and its hereditary form, 
hereditary nonpolyposis colorectal cancer. Gastrointestinal 
stromal tumor (GIST) development is associated with acti-
vating mutations of KIT proto-oncogene receptor tyrosine 
kinase (KIT) or platelet-derived growth factor receptor α 
(PDGFRA), which are oncogenes that predict the response 
to imatinib mesylate. In addition to KIT/PDGFRA mutations, 
other molecular alterations are important in GIST develop-
ment. In GISTs, the characterization of the MSI phenotype is 
scarce and the results are not consensual. The present study 
aimed to assess MSI in a series of 79 GISTs. The evaluation of 
MSI was performed by pentaplex polymerase chain reaction 
comprising five markers, followed by capillary electropho-
resis. The expression of MMR proteins was evaluated by 
immunohistochemistry. Regarding the KIT/PDGFRA/B-Raf 
proto-oncogene, serine/threonine kinase molecular profile of 
the 79 GISTs, 83.6% of the tumors possessed KIT mutations, 
10.1% had PDGFRA mutations and 6.3% were triple wild-type. 
The mutated‑PDGFRA cases were associated with gastric 
location and a lower mitotic index compared with KIT-mutated 
and wild-types, and these patients were more likely to be alive 
and without cancer. MSI analysis identified 4 cases with insta-
bility in one marker, however, additional evaluation of normal 
tissue and immunohistochemical staining of MMR proteins 
confirmed their microsatellite‑stable nature. The results of 
the present study indicated that MSI is not involved in GIST 
tumorigenesis and, therefore, cannot serve as a biomarker to 
immunotherapy response in GIST.
Introduction
Microsatellite instability (MSI) status has drawn attention as 
a guide to immunotherapy against different types of tumor (1). 
Immune checkpoint inhibitors represent a significant advance 
in precision medicine, inducing durable tumor responses even 
in patients with late-stage cancer who have failed to respond 
to multiple previous lines of therapy (1,2). Anti-programmed 
death (PD)-1 inhibitors, including pembrolizumab, are 
humanized monoclonal antibodies which block the interaction 
between PD-1 and its ligands, PD-L1 and PD-L2, and allow 
T cells to kill the tumor cells (1).
Notably, a phase II study (NCT01876511) in metastatic 
carcinomas demonstrated that the MSI phenotype constituted 
an important biomarker for patient response to immuno-
therapy (1). Most notably, the study revealed that immune 
checkpoint proteins, including PD‑1 and PD‑L1, were signifi-
cantly upregulated in tumors with MSI, enabling them to 
survive. In MSI colorectal cancer (CRC), PD-L1 is expressed 
on tumor-infiltrating lymphocytes and/or myeloid cells as 
opposed to tumor cells (1,2).
MSI is characterized by widespread somatic alterations in 
the length of nucleotide repeat sequences, which are known as 
microsatellites (3). The MSI phenotype is a marker of defects 
in the DNA mismatch repair (MMR) system during DNA 
replication (3,4). The MSI phenotype is present in all cases 
of hereditary nonpolyposis CRC syndrome, as well as ~15% 
of sporadic CRC, while it is less frequently observed in other 
tumors, including gastric, biliary tract, pancreas, ovary, prostate 
and small intestine tumors (1,5). In CRC, the presence of MSI 
is also associated with a number of clinicopathological features, 
including proximal location, poorly-differentiated tumors, low 
frequency of distant metastases and an improved prognosis (6).
Gastrointestinal stromal tumors (GISTs) are the most 
common mesenchymal neoplasms of the gastrointestinal 
tract (7), with a global annual incidence of 11-18 per 
million (8,9). GISTs are considered to originate from the 
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interstitial cells of Cajal, or a common stem/precursor 
cell (8,10), and usually arise in the stomach (40-70%) or small 
intestine (20-40%), and less frequently in the esophagus, 
colon and rectum (8,11). GISTs also occur elsewhere within 
the abdominal cavity, primarily in the omentum, mesentery 
or retroperitoneum (<5% of all GISTs), and these are referred 
to as extra-gastrointestinal tract tumors (12,13). Histologically, 
the spectrum of morphology includes spindle, epithelioid or 
mixed cells (14).
The malignant potential of GISTs ranges from entirely 
benign to aggressive tumors. However, ~40% of GISTs that are 
localized at the time of diagnosis eventually metastasize (13). 
The metastatic dissemination has a predilection to the liver, 
omentum, peritoneum and other intra-abdominal sites (13). 
The prognosis of patients with GISTs is based on criteria 
established by the Armed Forces Institutes of Pathology 
(AFIP) criteria (15), including tumor location, size and mitotic 
index. This criterion ranks the patients as benign, very low, 
low, intermediate and high risk (8).
The majority of GISTs are positive for the proto-oncogene 
receptor tyrosine kinase (KIT) protein (anti-CD117 is used to 
identify KIT), and this positivity acts as a crucial diagnostic 
marker for these tumors (8,16). KIT is a member of the type III 
receptor tyrosine kinase family, and the binding of its growth 
factor, stem cell factor (SCF), to the extracellular domain 
results in dimerization of the receptor and downstream activa-
tion of mitogen-activated protein kinase, phosphatidylinositol 
3-kinase and Janus kinase/signal transducers and activators of 
transcription pathways (13).
KIT gene mutations are present in 70-80% of GIST 
cases (17). These oncogenic mutations result in the constitu-
tive activation of the receptor and consequently, the activation 
of intracellular pathways (17). KIT mutations typically affect 
the juxtamembrane domain encoded by exon 11 (70% of 
cases), the extracellular domain encoded by exon 9 (6-15%) 
and the kinase I and II domains encoded by exons 13 and 17 
(2%) (17,18). In particular, deletions have been associated with 
a worse clinical outcome compared with other types of exon 11 
mutation, with shorter progression-free and overall survival 
times (9). In addition, GISTs harboring KIT exon 9 mutations 
are characterized by small bowel location, aggressive clinical 
characteristics (9,19) and decreased sensitivity to first line 
therapy compared with KIT exon 11 mutant tumors (9).
Another member of the tyrosine kinase receptor family, 
platelet-derived growth factor receptor α (PDGFRA), is also 
involved in GIST pathogenesis (16,20). Mutations in the 
PDGFRA gene occur in 5-7% of cases, in domains which are 
similar to those in the KIT gene (16,21). GISTs harbor mutations 
in the PDGFRA juxtamembrane domain (encoded by exon 12), 
the ATP-binding domain (encoded by exon 14) or the activa-
tion loop (encoded by exon 18) (21). The majority of GISTs 
with mutated-PDGFRA have a distinct phenotype, including 
gastric location, epithelioid morphology, variable/absent KIT 
expression as determined by immunohistochemistry and an 
indolent clinical course (22). In addition, mutations in exon 18 
of PDGFRA are associated with a lack of response to imatinib 
therapy (21). Consistent with their functional overlap, KIT and 
PDGFRA mutations are mutually exclusive in GISTs (8,16).
Between 10-15% of GISTs are KIT or PDGFRA 
wild-type (22). These tumors form a heterogeneous group, a 
Table I. Clinicopathological features of gastrointestinal 
stromal tumors.
Variable  Patients, n (%)
Sex
  Female 41 (46.6)
  Male 47 (53.4)
Histological subtype
  Spindle 67 (81.7)
  Epithelioid 12 (14.6)
  Mixed 3 (3.7)
Primary localization
  Esophagus 1 (1.1)
  Stomach 44 (50.0)
  Small intestine 25 (28.4)
  Rectum 6 (6.9)
  Mesentery 1 (1.1)
  Retroperitoneum 6 (6.9)
  Colon 1 (1.1)
  Othersa 4 (4.5)
Tumor size
  ≤5 cm 28 (37.3)
  5.1-10 cm 22 (33.3)
  >10 cm 25 (29.3)
Mitotic index
  ≤5 39 (58.2)
  >5 25 (37.3)
  6-10 3 (4.5)
AFIP risk classification
  Benign 7 (11.3)
  Very low 7 (11.3)
  Low 7 (11.3)
  Intermediate 9 (14.5)
  High 32 (51.6)
Imatinib
  Yes 44 (95.7)
  No 2 (4.3)
Local disease recurrence
  Absent 66 (77.6)
  Present 19 (22.4)
Metastasis
  Absent 47 (54.7)
  Present 39 (45.5)
KIT/PDGFRA/BRAF mutation status
  KIT 66 (83.6)
  PDGFRA 8 (10.1)
  BRAF 0 (0.0)
  Wild-type 5 (6.3)
Current status
  Mortality due to cancer 28 (31.8)
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number of which are driven by oncogenic mutations acting 
downstream of the receptor kinases, such as B-Raf proto-onco-
gene, serine/threonine kinase (BRAF) mutations (described in 
1.3% of all tumors) (23,24). A previous study demonstrated 
that wild-type GISTs exhibit a different genetic background, 
including mutation in succinate dehydrogenase (21). In either 
of these cases, there is poor response to first line therapy (9).
Molecular‑targeted agents are being utilized as first line 
treatment for GISTs, including imatinib mesylate and sunitinib 
maleate. These two agents are KIT/PDGFRA competitive 
inhibitors that stabilize the inactivated form of the recep-
tors, inhibiting downstream signaling activation (25-27). 
The median survival time for patients with advanced disease 
treated with imatinib is 5 years, with 34% of patients surviving 
>9 years (8). Despite this, the vast majority (≥80%) of patients 
eventually develop secondary resistance (13). Acquired muta-
tions in KIT or PDGFRA usually occur in the kinase domain 
and interfere with drug binding, causing resistance (9,21). The 
majority of mutations in exon 9 are 6-nucleotide duplications 
encoding Ala502-Tyr503, which require twice the normal 
dose of imatinib (800 mg/day) for optimal clinical results. In 
the PDGFRA gene, the most common mutation is a missense 
mutation in exon 18, which leads to substitution of Asp to Val 
(termed D842V) (19,28). This mutation is usually resistant to 
treatment with imatinib (19,28).
In GISTs, the characterization of MSI is limited and the 
results are controversial (29-31). Therefore, the present study 
aimed to assess the presence and frequency of MSI using an 
accurate methodology in a series of 88 Brazilian GISTs, and 
investigated the association with clinicopathological features 
of patients.
Patients and methods
Patient population and tissue samples. The present study 
analyzed 88 patients submitted to resection at Barretos Cancer 
Hospital (São Paulo, Brazil) between January 1989 and 
December 2012. A total of 79 primary GISTs were included 
in the KIT/PDGFRA molecular test and MSI analysis. The 
other 9 cases were excluded due to poor DNA quality and 
lower quantity. Clinicopathological data of patients were 
retrospectively obtained, including age, sex, tumor localiza-
tion and risk classification (according to AFIP criteria), local 
disease recurrence, metastasis, chemotherapy and follow-up 
status (as of March 2015). In addition, information concerning 
GIST molecular status (KIT, PDGFRA and BRAF mutations) 
was previously reported for 60 cases (32,33). The clinical and 
molecular data are summarized in Table I.
The average age of the individuals was 57±12.4 years old. 
The most common histological subtype was spindle cells, 
and the most common primary localization was the stomach, 
followed by small intestine, rectum and retroperitoneum, 
(Table I). The tumors were classified as high risk in 51.6% of 
cases and the majority of patients were treated with an oral 
administration of 400 mg of imatinib. Only 2 patients were 
treated with 5‑fluorouracil and/or etoposide. The majority of 
patients (54.7%) did not experience local recurrence or metas-
tasis. Of those that did, liver (66.7%) and lung (7.7%) were the 
most common sites of metastasis (Table I).
The present study was approved by the local ethical 
committees (approval no. 554/2011) of Barretos Cancer 
Hospital. The ethics committee of our institution authorized 
that no patient consent was required due to the retrospective 
nature of the study.
DNA isolation. DNA from samples that had been fixed 
in 10% formalin for 12-24 h at room temperature and then 
paraffin‑embedded was retrieved from 5‑µm cuts, following 
careful macrodissection of the tumor area and ensuring the 
presence of >75% of neoplastic cells. DNA extraction was 
performed using the QIAamp DNA Micro kit (Qiagen, Inc., 
Valencia, CA, USA), following the manufacturer's protocol, 
quantified by NanoDropVR 2000 (Thermo Fisher Scientific, 
Inc., Waltham, MA, USA) and stored at ‑20˚C until subsequent 
genetic analysis.
KIT/PDGFRA/BRAF mutations. KIT and PDGFRA mutational 
status was analyzed by polymerase chain reaction (PCR) 
amplification and subsequent DNA sequencing of exons 9, 
11, 13 and 17 to KIT and exon 12, 14 and 18 to PDGFRA, as 
previously described (32,33).
Tumors with wild-type KIT and PDGFRA mutations 
were analyzed for the presence of exon 15 BRAF V600E 
mutations as previously described (24). The quality of PCR 
products was confirmed with 1% agarose gel electrophoresis. 
DNA sequencing of the PCR product was performed using 
the BigDye Terminator version 3.1 cycle sequencing kit 
(Applied Biosystems; Thermo Fisher Scientific, Inc.) and an 
ABI 3500XL Genetic Analyzer (Applied Biosystems; Thermo 
Fisher Scientific, Inc.) in accordance with manufacturer's 
protocol.
MSI analysis. The MSI evaluation was performed using a 
multiplex PCR comprising five quasi‑monomorphic mono-
nucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24 
and NR-27) as previously reported (34-36). The primer 
sequences used were described in previous studies (34,35). 
Each antisense primer was end labeled with a fluores-
cent dye: 6-carboxyfluorescein for BAT-26 and NR-21; 
2'-chloro-7'-phenyl-1,4-dichloro-6-carboxyfluorescein for 
BAT-25 and NR-27; and 2,7,8-benzo-5-fluoro-2,4,7-tri-
chloro‑5‑carboxyfluorescein for NR‑24. PCR was performed 
using the Qiagen Multiplex PCR kit (Qiagen, Inc.), with 1 µl 
DNA at 50 ng/ml and the following thermocycling conditions: 
Table I. Continued.
Variable  Patients, n (%)
Current status
  Mortality due to other causes 2 (2.3)
  Alive with cancer 27 (30.7)
  Alive without cancer 28 (31.8)
AFIP, Armed Forces Institutes of Pathology; KIT, KIT proto-onco-
gene receptor tyrosine kinase; PDGFRA, platelet-derived growth 
factor receptor α. aOther localizations included rectovagina (2/4), 
vagina (1/4), and unknown (1/4).
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Table II. Association between KIT/PDGFRA mutation status and clinicopathological features of gastrointestinal stromal tumors.
Variable KIT mutation, n (%) PDGFRA mutation, n (%) Wild-type, n (%) P-valuea
Sex    1.000
  Female 32 (48.5) 4 (50.0) 2 (40.0)
  Male 34 (51.5) 4 (50.0) 3 (60.0)
Primary localization    0.398
  Esophagus 1 (1.5) 0 0
  Stomach 29 (43.9) 8 (100) 4 (80)
  Small intestine 20 (30.3) 0 0
  Rectum 5 (7.6) 0  1 (20)
  Mesentery 1 (1.5) 0 0
  Retroperitoneum 6 (9.1) 0 0
  Other 4 (6.1) 0 0
Tumor size    0.963
  ≤5 cm 19 (37.3) 4 (50.0) 2 (50.0)
  5.1-10 cm 13 (25.5) 2 (25.0) 1 (25.0)
  >10 cm 19 (37.3) 2 (25.0) 1 (25.0)
Mitotic index    0.018
  ≤5  24 (51.1) 6 (75.0) 3 (60.0)
  5.1-10 cm 1 (2.1) 2 (25.0) 0 (0.0)
  >10 22 (46.8) 0 (0.0) 2 (40.0)
AFIP risk classification    0.198
  Benign 3 (7.1) 1 (12.5) 1 (20.0)
  Very low 5 (11.9) 2 (25.0) 0 (0.0)
  Low 5 (11.9) 1 (12.5) 0 (0.0)
  Intermediate 4 (9.5) 2 (25.0) 2 (40.0)
  High 25 (59.5) 2 (25.0) 2 (40.0)
Metastasis    0.097
  Absent 34 (52.3) 7 (87.5) 4 (80.0)
  Present 31 (47.7) 1 (12.5) 1 (20.0)
Status at last follow-up    0.010
  Alive without cancer 16 (25.4) 7 (87.5) 3 (60.0)
  Alive with cancer 24 (38.1) 0 (0.0) 0 (0.0)
  Mortality due to cancer 21 (33.3) 1 (12.5) 2 (40.0)
  Mortality due to other causes 2 (3.2) 0 (0.0) 0 (0.0)
AFIP, Armed Forces Institutes of Pathology; KIT, KIT proto-oncogene receptor tyrosine kinase; PDGFRA, platelet-derived growth factor 
receptor α. aFisher's exact test.
Figure 1. Electropherogram of KIT-mutated gastrointestinal stromal tumor (exon 11, p.Glu554_Val559del).
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15 min at 95˚C; 40 cycles of 95˚C for 30 sec; 55˚C for 90 sec 
and 72˚C for 30 sec; and a final extension at 72˚C for 40 min. 
PCR products were then submitted to capillary electrophoresis 
on an ABI 3500XL Genetic Analyzer (Applied Biosystems; 
Thermo Fisher Scientific, Inc.) according to the manufacturer's 
protocol, and the results were analyzed using GeneMapper v4.1 
software (Applied Biosystems; Thermo Fisher Scientific, Inc.). 
In all analyses, the DNA from the HCT-15 cell line (ATCC® 
CCL-225™; American Type Culture Collection, Manassas, 
VA, USA) (MSI-high) was used as a positive control for MSI.
A previous study by our group determined the quasimono-
morphic variation range of each marker for the Brazilian 
population (36). Accordingly, samples were considered 
MSI-high when two or more markers were altered, MSI-low 
when one marker was altered and microsatellite stable (MSS) 
in the absence of instability. In the MSI-low cases, validation 
by analysis of normal tissue or the immunohistochemistry of 
the MMR enzymes in tumor tissue was recommended (36).
MMR immunohistochemistry. Briefly, 10% formalin fixed (for 
12‑24 h at room temperature) paraffin‑embedded tissue speci-
mens were cut into 4‑µm sections, which were deparaffinized 
by heating (75˚C for 4 min) and then were transferred to 
Autostainer Link 48 equipment (Dako; Agilent Technologies, 
Inc. Santa Clara, CA, USA) (37). The antigen retrieval process 
was performed in Tris‑EDTA buffer (pH 9.0) at 97˚C for 
20 min. The EnVision™ FLEX Wash Buffer (Dako; Agilent 
Technologies, Inc.) contained Tris with Tween-20 (pH 7.6). 
Endogenous peroxidases were blocked at room temperature 
with EnVision™ FLEX Peroxidase-Blocking reagent for 
20 min. The primary rabbit polyclonal anti-human anti-
bodies used in the present study were as follows: Anti-mutL 
homolog 1 (MLH1; dilution, 1:100; clone G168-728, ref. 
285M-1); anti-mutS homolog 2 (MSH2; dilution, 1:100; 
clone G219-1129, ref. 286M-1); anti-PMS1 homolog 2, 
mismatch repair system component (PMS2; dilution, 1:25; 
clone EPR3947, ref. 288R-1); and anti-mutS homolog 6 
(MSH6; dilution, 1:600; clone 44, ref. 287M-1). All primary 
antibodies were obtained from Dako (Agilent Technologies, 
Inc.) and were incubated at room temperature for 20 min. The 
secondary antibody was the EnVision™ FLEX/horseradish 
peroxidase anti‑rabbit and anti‑mouse IgG (<10 µg/ml) in 
10% animal serum in TBS (ref. RE7111; Agilent Technologies, 
Inc.), which was incubated at room temperature with the 
samples for 20 min. EnVision DAB solution was used for 
immunostaining visualization, and was incubated at room 
temperature with the samples for 10 min. Slides were coun-
terstained with Hematoxylin of Harris (EP-101071; EasyPath, 
São Paulo, Brazil) at room temperature for 5 min, according 
to manufacturer's protocol. A light microscope was used to 
analyze all specimens at magnification, x100‑400.
Statistical analysis. Associations between molecular and 
clinical data from patients were analyzed using the χ2 test or 
Fisher's test. Cumulative survival probabilities were calculated 
using the Kaplan-Meier method. Differences between survival 
rates were tested with the log-rank test. SPSS 19.0 software 
(IBM SPSS, Armonk, NJ, USA) was used for all statistical 
analysis. P<0.05 was considered to indicate a statistically 
significant difference.
Results
Molecular and clinical profile of GISTs. Of the 88 GISTs 
analyzed, 9 cases were excluded due to poor DNA quality and 
lower quantity, leaving a total of 79 GIST cases. KIT mutations 
were observed in 83.6% (66/79) of cases and 10.1% (8/79) of 
cases exhibited PDGFRA mutations (Table I). None of the 
remaining cases (n=5) exhibited BRAF mutations, leading to 
a frequency of 6.3% (5/79) wild-type cases. The KIT mutation 
was located at exon 11 in 58 cases (87.9%), exon 9 in 6 cases 
(9.1%) and exon 17 in 2 cases (3.0%) Fig. 1 depicts a represen-
tative electropherogram of a mutation in exon 11. Regarding 
PDGFRA, 5 cases were mutated at exon 18 (62.5%), 1 case 
was mutated at exon 12 (12.5%) and 2 cases were mutated at 
exons 12 and 18 (25.0%).
The associations between KIT/PDGFRA mutation status 
and GIST clinicopathological features are listed in Table II. 
All PDGFRA-mutated GISTs had a gastric location and 
PDGFRA‑mutation status was significantly associated with 
lower mitotic index (P=0.018; Table II). The average follow-up 
period was 4.3±3.2 years, and 87.5% of patients with PDGFRA 
Figure 2. Overall survival for KIT and PDGFRA-mutated and wild-type 
GISTs.
Figure 3. Electropherogram of fragment analysis in a representative gastro-
intestinal stromal tumor case, with the marker BAT-26 altered (9 nucleotides 
deletion, arrow).
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mutations were alive with no evidence of cancer, compared 
with 25.4% of patients with KIT-mutations (P=0.010). All KIT 
exon 9-mutated cases exhibited tumor progression following 
imatinib treatment, while 44.4% of the KIT exon 11-mutated 
cases had stable disease subsequent to chemotherapy (data not 
shown).
Kaplan-Meier survival analysis revealed that, despite the 
absence of statistical significance, the 5‑year overall survival 
rate was 66.1% for KIT‑mutated cases, and 80% for PDGFRA 
and wild-type cases (Fig. 2). No significance was observed in 
recurrence-free survival analysis among KIT, PDGFRA and 
wild-type groups (data not shown).
MSI analysis. The MSI analysis was successful in all 79 GIST 
cases. A total of 75 (~95%) samples exhibited a stable profile, 
while 4 primary GISTs exhibited instability in one marker. 
In total, 2 cases exhibited alteration of the BAT-26 marker, 
1 case exhibited alteration of the NR-21 marker and 1 case 
demonstrated instability in the BAT-25 marker (Fig. 3). 
Our previous study reported that the presence of instability 
in one marker in the Brazilian population may be due to 
polymorphic variants (36). Therefore, it was proposed that 
analysis of the MMR immunohistochemistry or the MSI 
analysis of paired normal DNA should be performed for 
these cases to accurately determine the MSI status of these 
patients. The investigation of MMR immunohistochemistry 
revealed positive staining for all MMR (MLH1, MSH2, 
MSH6 and PMS2) proteins analyzed (Fig. 4). In addition, the 
MSI analysis of paired normal DNA in all 4 cases revealed 
the same genotype in normal and tumor DNA. Thus, these 
results indicated that all 4 cases were MSS.
Discussion
Determination of MSI status appears to be a marker for 
novel treatments, and it may serve as a predictive marker 
for the selection of patients who may benefit from pembro-
lizumab, an anti-PD-1 immunotherapy (1). The data from 
this phase II trial support the hypothesis that MMR‑deficient 
tumors are more responsive to PD-1 blockade compared with 
MMR‑proficient tumors (1). However, there is still no data on 
clinical trials evaluating PD-1 agents in GISTs, despite the 
growing interest.
The MSI phenotype in GISTs is poorly-characterized 
and reports are not consensual. In the present study, MSI was 
analyzed in 79 GIST samples using a multiplex PCR comprising 
five quasi‑monomorphic mononucleotide repeat markers. In 
the 4 cases that exhibited alteration in only one marker, MSI 
analysis was performed in paired normal DNA and MMR 
immunohistochemistry was performed, which revealed the 
MSS nature of these samples. Therefore, MSI was not present 
in the present series of GISTs. These findings are in accordance 
Figure 4. Immunohistochemistry of mismatch repair proteins for 1 case with instability in one marker. Slides were visualized using DAB and counterstained 
using hematoxylin. (A) mutL homolog 1, (B) PMS1 homolog 2, (C) MSH6 and (D) MSH2. Magnification, x200. MSH, mutS homolog.
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with the first study addressing the presence of MSI in GISTs 
by Lopes et al (31), which analyzed 33 GISTs. However, other 
authors reported the presence of MSI in 5% (3/62) and 50% 
(10/22) of cases (29,30).
It was proposed that these discrepant results may have 
several causes. First, the number of cases analyzed in the 
aforementioned two studies was too small for consistent 
results (27,28). The present study examined 79 cases, which 
is the largest series that has undergone MSI status evaluation 
using molecular techniques. Secondly, distinct methodolo-
gies for MSI assessment were used, and the accuracy of MSI 
detection is known to be highly dependent on the techniques 
selected. Kose et al (30) used the BAT-26 marker in analysis 
of MSI, only in tumor DNA. Fukasawa et al (29) evaluated the 
loss of heterozygosity as well as MSI in paired normal and 
tumor DNA using dinucleotide markers dispersed on several 
chromosomes. Tissues were considered MSI-positive when 
one or more markers were altered. Notably, the two studies 
evaluated MSI in Japanese populations. This is particularly 
important due to the quasimonomorphic nature and the effect 
of the ancestry of the MSI markers. Buhard et al (34,35) 
studied the global population and identified polymorphisms 
in the BAT-26 marker in up to 3.3% of the Asiatic popula-
tions, whereas in Caucasian populations this marker exhibited 
a monomorphic nature.
In GISTs, the molecular profile serves as a classification 
system that is useful for diagnostic, prognostic and treatment 
planning purposes (19,22,38). In the present study, the KIT and 
PDGFRA profiles of the 79 GIST cases and their clinicopatho-
logical associations were similar to those previously reported 
in the literature (22). Mutations in KIT exon 11 were the most 
common oncogenic mutations observed in GISTs, followed by 
KIT exon 9. Exon 18 was also revealed to be the most frequently 
mutated PDGFRA region. PDGFRA-mutant GISTs frequently 
possessed characteristics of low-risk GIST, including a gastric 
primary site and a low mitotic index, as previously reported in 
the literature (19,22). In addition, a tendency for patients with 
PDGFRA mutations and those with wild-type GISTs to have 
a smaller risk of recurrence compared with patients with KIT 
mutations was observed.
In conclusion, using accurate MSI methodologies widely 
used for the assessment of CRC, a large series of confirmed 
GISTs was analyzed for the presence of genetic instability 
phenotypes. No cases with MSI were observed, and so it was 
concluded that the MMR system is proficient in patients with 
GISTs, and that MSI does not appear to be involved in GIST 
tumorigenesis.
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